AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Lysosome-associated membrane glycoprotein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P13473

UPID:

LAMP2_HUMAN

Alternative names:

CD107 antigen-like family member B; LGP-96

Alternative UPACC:

P13473; A8K4X5; D3DTF0; Q16641; Q6Q3G8; Q96J30; Q99534; Q9UD93

Background:

Lysosome-associated membrane glycoprotein 2 (LAMP2), also known as CD107 antigen-like family member B or LGP-96, plays a pivotal role in chaperone-mediated autophagy. This process is crucial for lysosomal degradation of proteins under stress or as part of normal protein turnover. LAMP2 binds target proteins like GAPDH, NLRP3, and MLLT11, directing them to lysosomal degradation. It is essential for autophagosome-lysosome fusion and efficient MHCII-mediated antigen presentation.

Therapeutic significance:

LAMP2's involvement in Danon disease, characterized by cardiomyopathy, vacuolar myopathy, and intellectual disability, underscores its therapeutic significance. Understanding LAMP2's role could unveil novel therapeutic strategies for lysosomal storage diseases and conditions related to autophagy dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.